Debiopharm Group and Mercury Therapeutics Sign Development and Commercialization of Debio 0930
News Aug 10, 2009
Debiopharm Group (Debiopharm) and Mercury Therapeutics, Inc. (Mercury) have announce the signature of an exclusive license agreement for the development and commercialization of Debio 0930, a small molecule activator of AMPK (adenosine monophosphate activated protein kinase) for the treatment of diabetes and metabolic diseases.
Activation of AMPK has been shown to lower fasting blood glucose levels and improve glucose disposal following a glucose challenge, two key goals in the management of type 2 diabetes.
Under the terms of the agreement, Debiopharm shall pay Mercury for continued research and development support, predefined advanced milestone payments during the development of the compound and a royalty based on net sales of commercialized product. First entry into man is expected for 2012.
“We are very enthusiastic about our collaboration with an experienced innovative biotech company like Mercury. Diabetes is a major cause of morbidity and mortality by disease globally and we are determined to improve the quality of patient’s lives by developing a new therapy,” said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group.”
“This alliance with Debiopharm represents important validation of Mercury’s technology and of the growing appreciation of AMPK as a novel drug target for metabolic diseases. The development of an orally available direct activator of AMPK has the potential to be a first-in-class therapeutic for type 2 diabetes, hyperlipidemia, and a number of indications in oncology,” added Dr. Neal Birnberg, CEO of Mercury, who was advised on this transaction by Katan Associates.
Cell Chimeras Provide Muscular Dystrophy BreakthroughNews
Fusing together healthy cells with those affected by Duchenne Muscular Dystrophy could improve muscle function.READ MORE
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018